AndroGel Lawsuit Trial Alleging The Testosterone Therapy Drug Caused Heart Attack Continues In Illinois

   

This AndroGel Lawsuit and other Testosterone Therapy Lawsuits Allege Prescription Low-T Medications Cause Heart Attacks and Stroke.

AndroGel Lawsuit testosterone-lawsuit-therapy-lawyerA second AndroGel lawsuit bellwether trial moves forward in Illinois this week over claims the testosterone therapy gel causes heart attacks. The AngroGel lawsuit represents over 6,000 testosterone lawsuits alleging AndroGel, Axiron and other prescription medications used to treat low testosterone levels in men may cause heart attacks, strokes and blood clots. Of the total number of Low-T complaints pending in a multidistrict litigation (MDL) in the Northern District of Illinois, more than 4,000 are brought against AbbVie and Abbot Laboratories, the maker and marketer of the popular AndroGel testosterone gel. (In re: Testosterone Replacement Therapy Product Liability Litigation – AndroGel Lawsuit MDL No. 2545)

“We are pleased that a jury will now hear the life-threatening side-effects that plaintiffs say they suffered after using a prescription testosterone product like AndroGel,” says Dr. François Blaudeau, founder of Southern Med Law.

Southern Med Law’s understanding of medical and legal issues involved in testosterone drug lawsuits empowers the firm’s attorneys to provide the aggressive and effective advocacy for men who believe they have been harmed by prescription testosterone products. If you or a loved one have been injured by testosterone replacement therapy medication, call Southern Med Law today at 205-547-5525 for a free, no-obligation testosterone therapy lawsuit review or by visiting www.southernmedlaw.com and filling out our online form.

The bellwether trial involves a man who was prescribed AndroGel in 2007 and suffered a heart attack in November 2012 at the age of 49. The plaintiff’s complaint contends AbbVie misrepresented AndroGel as a safe and effective treatment for hypogonadism, which is abnormally low testosterone levels in men not related to the aging process. The complaint states the company knew or should have known about the dangers of AndroGel and should have warned the public about the heart attack risks associated with the product. Peggy Pence, president and CEO of Symbion Research International Inc., a pharmaceutical consulting firm, testified last week that AbbVie had received reports of cardiovascular events occurring in people taking AndroGel and should have conducted more testing and updated the product’s label. (AndroGel Lawsuit Case No.14-9178, In re: Testosterone Replacement Therapy Product Liability Litigation – MDL No. 2545)

The AndroGel lawsuit trial comes three years after the U.S. Food and Drug Administration (FDA) launched a probe into all FDA-approved testosterone products. The FDA said in January 2014 that its investigation was prompted by studies that linked serious cardiovascular events with prescription testosterone replacement therapies. In March 2014, the agency required testosterone manufacturers to update their product labels and add information on the possible increased risk of heart attacks and strokes in patients taking testosterone.
[fda.gov/Drugs/DrugSafety/ucm383904.htm]
[fda.gov/Drugs/DrugSafety/ucm436259.htm]

The plaintiff in the second bellwether trial filed his AndroGel lawsuit in 2014, the same year the U.S. Judicial Panel on Multidistrict Litigation established an industrywide MDL for all testosterone lawsuits, regardless of the manufacturer. U.S. District Judge Matthew Kennelly, who is managing the MDL in Northern Illinois, has scheduled six AndroGel bellwether trials to go this year.

Besides AbbVie and Abbot Laboratories, other testosterone manufacturers in the MDL are:

•Actavis, Inc. and Watson Pharmaceuticals, which makes AndroDerm
•Auxilium Pharmaceuticals, Inc., which makes Testim
•Eli Lilly and Company and Lilly USA LLC, makers of Axiron
•Pharmaceuticals Inc., which makes Delatestryl and Fortesta
•Pfizer Inc. and its subsidiary, Pharmacia & Upjohn Co. which makes and
markets Depo-Testosterone
(In re: Testosterone Replacement Therapy ProductLiabilityLitigation – MDL No. 2545)

About Southern Med Law And Filing A Testosterone Drug Lawsuit

Throughout his career, Southern Med Law’s Founder, Dr. François Blaudeau, has worked hard to develop a strong reputation in healthcare litigation. Along with attorney Bleadeau, the firms attorneys have a strong knowledge of medical device and harmful drug litigaiton. They are strong advocates for fair legal representation of victims across the country.

Southern Med Law
François M. Blaudeau, MD JD FACHE FCLM Esquire
2224 1st Avenue North
Birmingham, Alabama 35203
Phone: (205) 547-5525
Fax: (205) 547-5526
francois@southernmedlaw.com
Medical Negligence/MedicalDevice/Pharma/Qui Tam
www.southenmedlaw.com
Like us on Facebook
Follow us on Twitter

This entry was posted in Southern Med Law | Article. Bookmark the permalink.